CD30 is a member of the
tumor necrosis factor receptor superfamily. CD30 was originally described as a
cell surface antigen on primary and cultured Hodgkin's and Reed-Sternberg cells. In this study, recombinant human
CD30 ligand was expressed on the surface of CV-1/EBNA cells and tested for
biologic activities on a variety of different CD30+ human
lymphoma cell lines.
CD30 ligand enhanced Ig secretion of Epstein-Barr virus (EBV)-immortalized, CD30+ lymphoblastoid B-cell lines, but not
Burkitt lymphoma lines. Recombinant
CD30 ligand enhanced proliferation of "T-cell-like"
Hodgkin's disease-derived cell lines and an
adult T-cell leukemia cell line, but not "B-cell-like"
Hodgkin's disease-derived cell lines, CD30+, EBV-immortalized lymphoblastoid B-cell lines, or CD30+ and EBV+
tumor B-cell
non-Hodgkin's lymphoma cell lines. In addition,
CD30 ligand mediated reduction of proliferation and viability, by induction of cytolytic cell death, of CD30+, large-cell anaplastic
lymphoma cell lines. Two new
antibodies, M44 and M67, against the
CD30 antigen demonstrated similar
biologic activities to the
CD30 ligand. Taken together, these data demonstrate pleiotropic
biologic activities of the
CD30 ligand on different CD30+
lymphoma cell lines and indicate that the CD30-CD30
ligand interaction might have a pathophysiologic role in Hodgkin's and some non-Hodgkin's
lymphomas.